X4 Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 93
- Market Cap
- $117.9M
- Website
- http://www.x4pharma.com
Drug-Drug Interaction Potential of Mavorixafor
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06914869
- Locations
- 🇺🇸
Parexel International LLC, Baltimore, Maryland, United States
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06858696
- Locations
- 🇺🇸
Catalina Research Institute, LLC, Rialto, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute/Alamo Medical Research, San Antonio, Texas, United States
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06056297
- Locations
- 🇩🇪
Universitaetsklinikum Carl Gustav Carus Tu Dresden, Dresden, Germany
🇬🇷Hellenic Airforce 251 General Hospital, Athens, Greece
🇬🇷University General Hospital of Heraklion, Iraklio, Greece
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04274738
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mass General Hospital Cancer Center, Boston, Massachusetts, United States
🇬🇷University of Athens, Athens, Greece
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT04154488
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸USF Health Department of Pediatrics, Saint Petersburg, Florida, United States
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03995108
- Locations
- 🇦🇺
Wesley Hospital, Auchenflower, Queensland, Australia
🇭🇺University of Debrecen, Affiliated Department of Infectology, Debrecen, Hajdu-Bihar, Hungary
🇫🇷CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique, Lyon, Rhne, France
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
- Conditions
- WHIM Syndrome
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- X4 Pharmaceuticals
- Registration Number
- NCT03087370
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT03005327
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇦🇺St. Vincent's Hospital, Fitzroy, Victoria, Australia
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02923531
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT02823405
- Locations
- 🇺🇸
Clinical Site, Salt Lake City, Utah, United States